The Vanguard Path study is led by researchers at the University of Oxford and funded with £1.9 million from the charity Prostate Cancer UK.
More than 40 of people are set to drop down a score banding after the changes, but Experian said it will not affect lending eligibility.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback